UroGen (URGN): Market Capitalization-to-Revenue Ratio

Symbol and logo of brand UroGen (URGN)

The price-to-sales valuation clearly demonstrates the impact of stringent FDA requirements and patent protection on UroGen Pharma Ltd. (URGN) dynamics, with 5.10 serving as the current value of the metric. High physician confidence in urothelial therapy confirms the company's status as an innovator, while the unique hydrogel enables seamless global business scaling with minimal production costs.

URGN UroGen Pharma Ltd. P/S Multiple (07/04/2022 - 11/15/2026)

Metric breakdowns and analytics for UroGen Pharma (URGN)

- stock value and consensus price forecast:
- stock exchange capitalization data:
Summary company analytics:UroGen Pharma Ltd, URGN
Mass-produced product of urogen.com

The P/S ratio reflects the market value of a business relative to its revenue, allowing for an assessment of an asset's fair value through the lens of generated sales. Analyzing the median P/S helps compare the capitalization of UroGen Pharma Ltd. (URGN) with the efficiency of its modernized oncology drug production facilities, determining whether the stock price is justified by current capacity utilization and revenue growth rates.

Competitors of UroGen Pharma Ltd.

ONC - Price to Sales|P/S Multiple HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Price to Sales|ascentage.com - P/S Multiple|Market Capitalization-to-Revenue Ratio CGON (cgoncology.com)|BCAX: P/S Multiple|PSNL - Price-to-Revenue Coefficient|ERAS (Erasca Oncology) - P/S Multiple|P/S Multiple Delcath Systems, Inc.|Price-to-Revenue Ratio ymabs.com (YMAB)|Price-to-Revenue Ratio AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Market Cap to Revenue|Accuray Inc. (ARAY) - Price to Sales|SELLAS Life Sciences Group, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Price-to-Revenue Ratio|HURA - Price-to-Revenue Coefficient|TARA (Protara Therapeutics, Inc.) - P/S Multiple|P/S Multiple Fate Therapeutics Inc|P/S Multiple WHWK|P/S Multiple TScan Therapeutics Inc (TCRX)|Price-to-Revenue Ratio championsoncology.com CSBR|XBIT - Market Cap to Revenue|CVM - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio OSTX (OS Therapies)|RADX: P/S Multiple|Artiva Biotherapeutics Inc. - Market Capitalization-to-Revenue Ratio|ANL (Adlai Nortye) - P/S Multiple|P/S Multiple verupharma.com|Market Cap to Revenue TPST (tempesttx.com)|Market Cap to Revenue Xilio Therapeutics Inc XLO|P/S Multiple RENB (Enochian BioSciences)|Mural Bio - Price-to-Revenue Ratio|KAPA - Price-to-Revenue Ratio|OnKure Therapeutics (OKUR) - Market Cap to Revenue|GDTC: P/S Multiple|Price to Sales Curis Corp (CRIS)|APLM (apollomicsinc.com) - P/S Multiple|Market Cap to Revenue Tharimmune Corp (THAR)|P/S Multiple ADVB|GNPX - Price to Sales|Price-to-Revenue Ratio calidibio.com CLDI|SBFM - Market Cap to Revenue|XBIO - Price-to-Revenue Ratio|SLRX: Price-to-Revenue Ratio|Purple Biotech (PPBT) - Price-to-Revenue Ratio|AON - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue BGNE|P/S Multiple Checkpoint Therapeutics Inc.|P/S Multiple ELEV|Market Cap to Revenue iCAD ICAD|P/S Multiple IKNA (Ikena Oncology, Inc.)|Market Capitalization-to-Revenue Ratio NTBL|Viracta Therapeutics, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Market Cap to Revenue|Market Cap to Revenue Ascentage Pharma Group Ltd